Literature DB >> 10619567

Alterations in nigrostriatal dopaminergic function within BDNF mutant mice.

D E Dluzen1, G M Story, K Xu, J Kucera, J M Walro.   

Abstract

The influence of brain-derived neurotrophic factor (BDNF) upon the nigrostriatal dopaminergic system was evaluated in weanling and adult mice carrying a targeted inactivated BDNF gene. Regional specificity of this BDNF mutation was assessed by assaying catecholamine concentrations within the corpus striatum, hypothalamus, and olfactory bulbs. In weanling mice dopamine, but not norepinephrine, concentrations within the corpus striatum of homozygous mutant (-/-) mice were significantly reduced with levels being 54% that of the wild-type controls (+/+) and 49% that of the heterozygous mutant (+/-) mice. While no differences were obtained among the three genotypes for hypothalamic dopamine, norepinephrine concentrations of -/- mice were significantly lower, being 62% of +/+ mice and 49% of +/- mice. The dopamine concentrations of -/- mice within the olfactory bulb were significantly reduced (69%) compared to the +/-, but not +/+ mice. Olfactory bulb norepinephrine concentrations showed a statistically significant difference among each of the three conditions with minimal levels in -/- mice (62% of +/+ and 45% of +/-). In the adults, catecholamine concentrations were measured only in +/+ and +/- mice since -/- mice do not typically survive past 21 days. Dopamine, but not norepinephrine, concentrations within the corpus striatum were significantly increased (116%) in +/- compared to +/+ mice. No other statistically significant differences were obtained in catecholamine concentrations within the hypothalamus or olfactory bulb in these adult mice. These results show that homozygous BDNF mutations produce severe depletions within the nigrostriatal dopaminergic system and substantial reductions of norepinephrine within the hypothalamus and olfactory bulb. Interestingly, maximal catecholamine concentrations for all areas sampled at both ages were observed in the +/- mice. These latter findings may indicate some subtle changes in catecholamine functions resulting from a heterozygous BDNF mutation.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 10619567     DOI: 10.1006/exnr.1999.7225

Source DB:  PubMed          Journal:  Exp Neurol        ISSN: 0014-4886            Impact factor:   5.330


  19 in total

1.  Effects of brain-derived neurotrophic factor on dopaminergic function and motor behavior during aging.

Authors:  H A Boger; P Mannangatti; D J Samuvel; A J Saylor; T S Bender; J F McGinty; A M Fortress; V Zaman; P Huang; L D Middaugh; P K Randall; L D Jayanthi; B Rohrer; K L Helke; A-C Granholm; S Ramamoorthy
Journal:  Genes Brain Behav       Date:  2010-10-19       Impact factor: 3.449

2.  Aberrant striatal dopamine transmitter dynamics in brain-derived neurotrophic factor-deficient mice.

Authors:  Kelly E Bosse; Francis K Maina; Johnna A Birbeck; Marion M France; Joseph J P Roberts; Michelle L Colombo; Tiffany A Mathews
Journal:  J Neurochem       Date:  2011-12-02       Impact factor: 5.372

Review 3.  The BDNF gene Val66Met polymorphism as a modifier of psychiatric disorder susceptibility: progress and controversy.

Authors:  M Notaras; R Hill; M van den Buuse
Journal:  Mol Psychiatry       Date:  2015-03-31       Impact factor: 15.992

4.  Developmental expression of neurotrophins and their receptors in postnatal rat ventral midbrain.

Authors:  Suzanne Numan; Christine M Gall; Kim B Seroogy
Journal:  J Mol Neurosci       Date:  2005       Impact factor: 3.444

5.  FTY720 Improves Behavior, Increases Brain Derived Neurotrophic Factor Levels and Reduces α-Synuclein Pathology in Parkinsonian GM2+/- Mice.

Authors:  Guadalupe Vidal-Martinez; Katherine Najera; Julie D Miranda; Carolina Gil-Tommee; Barbara Yang; Javier Vargas-Medrano; Valeria Diaz-Pacheco; Ruth G Perez
Journal:  Neuroscience       Date:  2019-05-23       Impact factor: 3.590

6.  Association of the met66 allele of brain-derived neurotrophic factor (BDNF) with smoking.

Authors:  Undine E Lang; Thomas Sander; Falk W Lohoff; Rainer Hellweg; Malek Bajbouj; Georg Winterer; Jürgen Gallinat
Journal:  Psychopharmacology (Berl)       Date:  2006-12-21       Impact factor: 4.530

Review 7.  Neurotrophic factors in neurodegenerative disorders : potential for therapy.

Authors:  Fabio Fumagalli; Raffaella Molteni; Francesca Calabrese; Paola Francesca Maj; Giorgio Racagni; Marco Andrea Riva
Journal:  CNS Drugs       Date:  2008       Impact factor: 5.749

8.  Involvement of BDNF in age-dependent alterations in the hippocampus.

Authors:  Oliver von Bohlen und Halbach
Journal:  Front Aging Neurosci       Date:  2010-08-13       Impact factor: 5.750

9.  Brain-derived neurotrophic factor gene variation influences cerebrospinal fluid 3-methoxy-4-hydroxyphenylglycol concentrations in healthy volunteers.

Authors:  Erik G Jönsson; Peter Saetre; Bodil Edman-Ahlbom; Anna Sillén; Agneta Gunnar; Dimitrios Andreou; Ingrid Agartz; Göran Sedvall; Håkan Hall; Lars Terenius
Journal:  J Neural Transm (Vienna)       Date:  2008-09-10       Impact factor: 3.575

10.  Amphetamine-induced locomotion and gene expression are altered in BDNF heterozygous mice.

Authors:  A J Saylor; J F McGinty
Journal:  Genes Brain Behav       Date:  2008-08-04       Impact factor: 3.449

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.